Pharmacokinetics and pharmacogenetics of tacrolimus in renal transplant patients dr. R.A.M. Op den Buijsch Chapter 01 – Outline and aim of the thesis Chapter 02 – Pharmacokinetics and pharmacogenomics of tacrolimus; a review submitted in an adapted form Chapter 03 – Comparison of DNA isolation kits to extract DNA from whole blood samples current genomics 2006;7:73-8 Chapter 04 – Genotyping of the pregnane X receptor A11156C polymorphism with locked nucleic acid containing fluorogenic probes the pharmacogenomics journal 2005;5:72-4 Chapter 05 – Rapid genotyping of the organic anion transporter polypeptide 1B1 polymorphisms A388G and T521C with real-time polymerase chain reaction fluorescence resonanceenergy transfer assays pharmacogenomics 2005;6:393-7 Chapter 06 – Evaluation of limited sampling strategies for tacrolimus european journal of clinical pharmacology: in press Chapter 07 – Influence of different allelic variants of the cytochrome 3A and adenosine triphosphate-binding casserre B1 gene the tacrolimus pharmacokinetic profile of chinese renal transplant recipients Pharmacogenomics 2006;7:563-74 Chapter 08 – Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms Fundamental & Clinical Pharmacology, 2007;21:427-35 Chapter 09 – Cytochrome P450 (CYP3A7) 1C allelic variant is associated with the tacrolimus pharmacokinetics in renal transplant recipients Submitted Chapter 10 – Influence of allelic variants of uridine diphosphate-glucuronosyltransferase (UGT) 2B7 on the tacrolimus exposure Submitted Chapter 11 – Pregnane X receptor (PXR) polymorphisms involved in the tacrolimus pharmacokinetics Submitted Chapter 12 – Influence of pregnane X receptor (PXR) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Submitted Chapter 13 – General discussion Terug
NL
EN